Tags : BL-8040

Regulatory

BioLineRx’s Motixafortide (BL-8040) Receives EC’s ODD to Treat Pancreatic Cancer

Shots: The EC has granted ODD to Motixafortide (BL-8040) for the treatment of pancreatic cancer following the positive COMP’s opinion The ODD designation is based on initial data of ongoing P-IIa COMBAT/KEYNOTE-202 study assessing the combination of BL-8040 + Keytruda (pembrolizumab) + CT in patients with m-pancreatic cancer Motixafortide is a selective inhibitor of the […]Read More